Gene therapy targets in heart failure: the path to translation

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Genetics

Background:

• Heart failure (HF) remains a significant clinical challenge despite therapeutic advances.
• Key intracellular signaling pathways, including beta-adrenergic receptor (β-AR) signaling and calcium (Ca2+) handling, are disrupted in HF.
• Current HF treatments do not directly target these fundamental intracellular abnormalities.

Purpose of the Study:

• To review the potential of gene therapy for correcting intracellular signaling defects in heart failure.
• To examine current gene therapy vector technologies and delivery strategies for cardiovascular applications.
• To identify promising gene therapy constructs and analyze challenges for clinical translation.

Main Methods:

• Literature review of preclinical and clinical studies on gene therapy for heart failure.
• Analysis of vector systems (e.g., viral vectors) and delivery methods for cardiac gene transfer.
• Evaluation of gene therapy approaches targeting β-AR signaling, Ca2+ dysregulation, and other HF-related molecular pathways.

Main Results:

• Gene therapy demonstrates potential to restore normal intracellular signaling in preclinical HF models.
• Various vector technologies show promise for efficient cardiac gene delivery.
• Specific gene therapy strategies are being developed to address key molecular deficits in HF.

Conclusions:

• Gene therapy represents a novel therapeutic avenue for heart failure by targeting underlying molecular derangements.
• Overcoming challenges in vector delivery, safety, and efficacy is crucial for clinical success.
• Further research and strategic development are needed to translate preclinical gene therapy findings into effective HF treatments.